Gain Therapeutics, Inc.(GANX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GANX Gain Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

4.14

+0.03

+0.73%

盘后4.17

+0.03+0.72%

19:56 EST

High4.30	Low4.03	Vol1.87M
Open4.20	D1 Closing4.11	Amplitude6.57%
Mkt Cap159.23M	Tradable Cap153.69M	Total Shares38.46M
T/O7.78M	T/O Rate5.03%	Tradable Shares37.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GANX","market":"US","secType":"STK","nameCN":"Gain Therapeutics, Inc.","latestPrice":4.14,"timestamp":1765573200000,"preClose":4.11,"halted":0,"volume":1866306,"hourTrading":{"tag":"盘后","latestPrice":4.17,"preClose":4.14,"latestTime":"19:56 EST","volume":30549,"amount":127268.9835,"timestamp":1765587369161},"delay":0,"floatShares":37123600,"shares":38462100,"eps":-0.637049,"marketStatus":"Market Closed","change":0.03,"latestTime":"12-12 16:00:00 EST","open":4.2,"high":4.3,"low":4.03,"amount":7783323.726711,"amplitude":0.065693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.637049,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1616040000000,"exchange":"NASDAQ","adjPreClose":4.11,"preHourTrading":{"tag":"盘前","latestPrice":4.26,"preClose":4.11,"latestTime":"09:03 EST","volume":7967,"amount":33607.870904899995,"timestamp":1765548185555},"postHourTrading":{"tag":"盘后","latestPrice":4.17,"preClose":4.14,"latestTime":"19:56 EST","volume":30549,"amount":127268.9835,"timestamp":1765587369161},"volumeRatio":1.1485090047052813,"impliedVol":6.1554,"impliedVolPercentile":0.976},"requestUrl":"/m/hq/s/GANX","defaultTab":"news","newsList":[{"id":"2590537540","title":"LIVE MARKETS-Stocks gain, yields little changed after Fed's hawkish cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537540?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:28","pubTimestamp":1765394883,"startTime":"0","endTime":"0","summary":"CLICK HEREFED DAY DATA DUET: EMPLOYMENT COSTS, MORTGAGES CLICK HERESTOCKS MIXED, TECH WEAKENS BEFORE EXPECTED FED RATE CUT CLICK HEREGIMME CREDIT FLAGS BIG DEBT RISKS IN NETFLIX'S WARNER BROS DISCOVERY DEAL CLICK HERESTAPLES STUCK: HSBC WARNS 2026 WON'T BE A PICNIC FOR CONSUMER GIANTS CLICK HEREHIGH HO, SILVER!CLICK HEREBELLIES PINCHED AS CENTRAL BANK EXPECTATIONS SHIFT CLICK HEREONE BITCOIN BULL HAS CUT THEIR FORECAST AS \"COLD BREEZE\" BLOWS CLICK HERESTOXX DIPS CLICK HEREBEFORE THE BELL: EUROPE DIPS ON FED DAY; DELIVERY HERO SHINES CLICK HEREONE LAST HURDLE REMAINS FOR THE YEAR CLICK HERE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"23fbf5c26d4af89ceb24828413619cee","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nL1N3XG0Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","BK4532","LU0882574139.USD","LU2362541513.USD","LU1674673428.USD","LU0320765059.SGD","LU0234570918.USD","IE00B19Z9505.USD","IE00B19Z8W00.USD","LU0210536198.USD","IE00BQXX3C00.GBP","LU0079474960.USD","LU1435385759.SGD","LU1988902786.USD","LU2326559502.SGD","LU1366192091.USD","LU0980610538.SGD","LU1720051017.SGD","BK4587","BK4548","LU0256863811.USD","LU1720051108.HKD","LU2361045086.USD","LU1316542783.SGD","LU0225283273.USD","LU0353189680.USD","BK4108","LU1674673691.USD","BK4507","BK4551","LU2108987350.USD","LU0203201768.USD","LU2860962120.EUR","LU0719512351.SGD","BK4566","LU2552382058.USD","LU2237957902.USD","LU0642271901.SGD","LU0109391861.USD","IE00BQXX3D17.EUR","LU0672654240.SGD","LU0868494708.USD","LU0106261372.USD","LU0256863902.USD","LU0477156953.USD","LU0417517546.SGD","BK4125","LU1046421795.USD","LU1232071149.USD","LU0077335932.USD","LU1548497426.USD","LU1778281490.HKD","LU2552382215.SGD","LU2362541273.HKD","LU1064131342.USD","IE00B19Z8X17.USD","LU0130102774.USD","LU2361044865.SGD","BK4585","BK4588","IE00BQXX3F31.USD","LU0097036916.USD","LU2362540622.SGD","SGXZ23171101.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LIVE","LU0130517989.USD","BK4581","LU0648001328.SGD","LU1989764664.SGD","LU1429558221.USD","LU0006306889.USD","LU0353189763.USD","LU0149725797.USD","IE00BKPKM429.USD","LU1814569148.SGD","LU0708995401.HKD","LU0868494617.USD","LU0942090050.USD","LU2357305700.SGD","BK4524","LU0234572021.USD","LU2264538146.SGD","LU1069344957.HKD","LU2552382132.HKD","LU0215105999.USD","BK4534","LU2087625088.SGD","LU2543165471.USD","LU0127658192.USD","BK4598","LU2237957811.SGD","LU1823568750.SGD","SG9999004303.SGD","SGXZ81514606.USD","BK4527","LU0082616367.USD","LU1035775433.USD","LU0786609619.USD","LU0203202063.USD","SGXZ99366536.SGD","SGXZ51526630.SGD","LU0210533765.USD","LU2361044949.HKD","LU1201861249.SGD","LU2896262040.SGD","GANX","LU1127390331.HKD","LU1267930730.SGD"],"gpt_icon":1},{"id":"2587730664","title":"Gain Therapeutics Announces New Stock Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2587730664","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587730664?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:31","pubTimestamp":1764365484,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Gain Therapeutics ( ($GANX) ). Gain Therapeutics, Inc., a company involved in the sale of common stock, announc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-announces-new-stock-offering-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-announces-new-stock-offering-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GANX","BK4139"],"gpt_icon":0},{"id":"2587737434","title":"BRIEF-Gain Therapeutics Files Prospectus For $35.5 Million Stock Sale - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587737434","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587737434?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:06","pubTimestamp":1764364010,"startTime":"0","endTime":"0","summary":"BRIEF-Gain Therapeutics Files Prospectus For $35.5 Million Stock Sale - SEC FilingNov 28  - Gain Therapeutics Inc GANX.O:GAIN THERAPEUTICS INC - FILES PROSPECTUS FOR $35.5 MILLION STOCK SALE - SEC FILINGSource text: [ID:n0001104659-25-116947]Further company coverage: GANX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GANX"],"gpt_icon":0},{"id":"2587673748","title":"Gain Therapeutics Inc - Files Prospectus for $35.5 Mln Stock Sale - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587673748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587673748?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:05","pubTimestamp":1764363905,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GANX"],"gpt_icon":0},{"id":"2584369631","title":"Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2584369631","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584369631?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:00","pubTimestamp":1763640020,"startTime":"0","endTime":"0","summary":"Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase  to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL7LzDZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","BK4585","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","GANX","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584136254","title":"Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136254","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584136254?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:00","pubTimestamp":1763640000,"startTime":"0","endTime":"0","summary":"GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191774/0/en/Gain-Therapeutics-Presents-Preclinical-GT-02287-Data-at-Neuroscience-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PD","BK4139","BK4023","BK4585","GANX","LU1169589451.USD","LU1169590202.USD","GT","BK4119"],"gpt_icon":0},{"id":"2583562016","title":"Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562016","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562016?lang=en_us&edition=fundamental","pubTime":"2025-11-16 01:26","pubTimestamp":1763227572,"startTime":"0","endTime":"0","summary":"BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November 13. Thomas Shrader’s rating is based...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-gain-therapeutics-promising-clinical-trial-results-and-stable-financial-health-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-gain-therapeutics-promising-clinical-trial-results-and-stable-financial-health-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GANX"],"gpt_icon":0},{"id":"2583436534","title":"Gain Therapeutics Reports Continued Progress Amid Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2583436534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583436534?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:34","pubTimestamp":1763008459,"startTime":"0","endTime":"0","summary":"Gain Therapeutics, Inc. ( ($GANX) ) has released its Q3 earnings. Here is a breakdown of the information Gain Therapeutics, Inc. presented to its i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-reports-continued-progress-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-reports-continued-progress-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","PRGS","BK4139","GANX"],"gpt_icon":0},{"id":"2582137562","title":"Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582137562","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582137562?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:14","pubTimestamp":1762949685,"startTime":"0","endTime":"0","summary":"Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.17) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799248/gain-therapeutics-q3-eps-0-15-beats-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX"],"gpt_icon":0},{"id":"2582375824","title":"Gain Therapeutics Q3 EPS USD -0.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375824?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:08","pubTimestamp":1762949318,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXBAFC5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GANX"],"gpt_icon":0},{"id":"2582373234","title":"Gain Therapeutics Completes Phase 1b Enrollment and Reports Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373234","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373234?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948892,"startTime":"0","endTime":"0","summary":"Gain Therapeutics Inc. reported its financial results for the third quarter of 2025 and provided a corporate update. The company completed enrollment in its Phase 1b study evaluating GT-02287 for Parkinson's Disease, with a total of 21 participants-surpassing the original target of 15. Of these, 16 have completed 90 days of dosing, and the remaining 5 are expected to finish in December 2025. The study includes patients with or without GBA1 mutations. Initial data presented from the Phase 1b study suggest GT-02287 may have a disease-slowing effect, as indicated by stabilization and improvement in Movement Disorder Society Unified Parkinson's Disease Rating Scale  scores after approximately 30 days of administration. The company also received approval from Australian health authorities to extend the Phase 1b study duration, allowing participants to continue treatment for up to 12 months. Approximately 80% of participants have either joined or expressed interest in the extension phase. An","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLb4slR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","GANX","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2582373218","title":"Press Release: Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373218","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373218?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action. Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025. Received approval from the Australian health authorities to extend the duration of the Phase 1b study, allowing participants to continue treatment with GT-02287 for a total of 12 months; with a majority of subjects electing to participate in the study extension. Analysis of functional changes and biomarker activity at 90 days expected to be available during 4Q 2025. Recent data presented at the International Congress of Parkinson's Disease and Movement Disorders demonstrated improvement in MDS-UPDRS scores after 90 days of dosing in the first nine pa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GT","LU1169589451.USD","BK4139","BK4218","GANX","BK4588","LU1169590202.USD","R","BK4181","BK4022","BK4585","PD","BK4023","BK4119","PK","BK4232"],"gpt_icon":0},{"id":"2579117897","title":"Gain Therapeutics Unveils GT-02287 Parkinson’s Therapy Data at Neuroscience 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579117897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579117897?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:00","pubTimestamp":1761822034,"startTime":"0","endTime":"0","summary":"Gain Therapeutics, Inc., a clinical-stage biotechnology company, announced it will present new research on its small molecule allosteric modulator, GT-02287, at the upcoming Society for Neuroscience annual meeting, Neuroscience 2025. The poster presentation, scheduled for November 19, 2025, will focus on the therapeutic potential of GT-02287, which targets the lysosomal enzyme glucocerebrosidase  and demonstrates activity at both lysosomes and mitochondria. The results of this research will be presented at the conference and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 30, 2025, and is sole","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL4h4dhB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","GANX","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","BK4585","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2575710001","title":"Gain Therapeutics to Attend the 2025 Maxim Growth Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710001","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710001?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612400,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., Oct.  16, 2025  (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167767/0/en/Gain-Therapeutics-to-Attend-the-2025-Maxim-Growth-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMF","GANX","BK4211"],"gpt_icon":0},{"id":"2575176796","title":"Gain Therapeutics Inc : Btig Cuts Target Price to $5 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2575176796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575176796?lang=en_us&edition=fundamental","pubTime":"2025-10-16 13:17","pubTimestamp":1760591820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX12V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GANX","BK4139"],"gpt_icon":0},{"id":"2575832427","title":"Analysts Are Bullish on These Healthcare Stocks: Candel Therapeutics (CADL), Gain Therapeutics (GANX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575832427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575832427?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:30","pubTimestamp":1760524220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and Gai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-candel-therapeutics-cadl-gain-therapeutics-ganx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-candel-therapeutics-cadl-gain-therapeutics-ganx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBI","BK4112","BK4539","BK4585","HCSG","BK4137","LU0029874061.USD","BK4588","LU0128526141.USD","CADL","LABU","XLV","GANX","BK4581"],"gpt_icon":0},{"id":"2575788114","title":"Gain Therapeutics Price Target Maintained With a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2575788114","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575788114?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:14","pubTimestamp":1760523240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GANX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 15, 2025 06:14 ET (10:14 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX"],"gpt_icon":0},{"id":"2575408755","title":"Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2575408755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575408755?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:25","pubTimestamp":1760354700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GANX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 07:25 ET (11:25 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX"],"gpt_icon":0},{"id":"2574191235","title":"Gain Therapeutics Inc reduces board size to seven after Eric Richman resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2574191235","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574191235?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:31","pubTimestamp":1760041901,"startTime":"0","endTime":"0","summary":"Gain Therapeutics Inc. announced that Eric Richman has resigned from its Board of Directors, effective immediately. Following his departure, the size of the Board has been reduced from eight to seven members. The company stated that Richman's resignation was not due to any disagreement regarding company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL3Nt0bz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","BK4139"],"gpt_icon":0},{"id":"2574156916","title":"Gain Therapeutics to Host Virtual KOL Event Highlighting GT02287 Data for Parkinsons Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2574156916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574156916?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:00","pubTimestamp":1760007646,"startTime":"0","endTime":"0","summary":"Gain Therapeutics Inc. will host a virtual key opinion leader event on October 14, 2025, at 4:00 p.m. EST. The event will focus on biomarkers, clinical endpoints, and emerging data from the Phase 1b clinical study of GT-02287 for Parkinson's disease, highlighting its safety and trending improvements in MDS-UPDRS scores.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL7l2HBs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","GANX","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","BK4585","IE00B64PRP62.GBP","NDAQ","BK4588","LU2210149790.SGD","LU2210150020.SGD","BK4112"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gaintherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0753},{"period":"1month","weight":0.4034},{"period":"3month","weight":1.494},{"period":"6month","weight":1.3931},{"period":"1year","weight":1.479},{"period":"ytd","weight":0.9167}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.04251},{"month":2,"riseRate":0.5,"avgChangeRate":0.033968},{"month":3,"riseRate":0.5,"avgChangeRate":0.000853},{"month":4,"riseRate":0.4,"avgChangeRate":-0.092023},{"month":5,"riseRate":0,"avgChangeRate":-0.120354},{"month":6,"riseRate":0.4,"avgChangeRate":-0.07139},{"month":7,"riseRate":0.2,"avgChangeRate":-0.110684},{"month":8,"riseRate":0.4,"avgChangeRate":0.009572},{"month":9,"riseRate":0.2,"avgChangeRate":0.082565},{"month":10,"riseRate":0.6,"avgChangeRate":0.068637},{"month":11,"riseRate":0.4,"avgChangeRate":0.045675},{"month":12,"riseRate":0.8,"avgChangeRate":0.129891}],"exchange":"NASDAQ","name":"Gain Therapeutics, Inc.","nameEN":"Gain Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gain Therapeutics, Inc.(GANX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gain Therapeutics, Inc.(GANX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gain Therapeutics, Inc.,GANX,Gain Therapeutics, Inc.股票,Gain Therapeutics, Inc.股票老虎,Gain Therapeutics, Inc.股票老虎国际,Gain Therapeutics, Inc.行情,Gain Therapeutics, Inc.股票行情,Gain Therapeutics, Inc.股价,Gain Therapeutics, Inc.股市,Gain Therapeutics, Inc.股票价格,Gain Therapeutics, Inc.股票交易,Gain Therapeutics, Inc.股票购买,Gain Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gain Therapeutics, Inc.(GANX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gain Therapeutics, Inc.(GANX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction